AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS.
About This Bill
Latest Action · Jul 23, 2026
Signed by Governor
Session
153
Introduced
May 19, 2026
Primary Sponsor
Melissa Minor-Brown· primary
Summary
Highlight any text to annotate
This Act modernizes Delaware law by adding modern medical treatment options biologics or biosimilars to the step therapy exception process. The current law was passed before biosimilars were widely available. Biosimilars are to biologics what generic drugs are to traditional drugs once their exclusivity expires.
This revision adds an exclusion to step therapy protocol exceptions for interchangeable biologics and biosimilars.